Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes

Transgenic mice overexpressing growth hormone (GH) have been extensively used to study the chronic effects of elevated serum levels of GH. GH is known to have many acute effects in the liver, but little is known about the chronic effects of GH overexpression on hepatic gene expression. Therefore, we...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology: endocrinology and metabolism 2003-09, Vol.48 (3), p.E504-E511
Main Authors: OLSSON, Bob, BOHLOOLY-Y, Mohammad, BRUSEHED, Ola, ISAKSSON, Olle G. P, AHREN, Bo, OLOFSSON, Sven-Olof, OSCARSSON, Jan, TÖRNELL, Jan
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cattle
Fundamental and applied biological sciences. Psychology
Genes
Hormones
Metabolism
Physical growth
Rodents
Transgenic animals
Vertebrates: endocrinology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transgenic mice overexpressing growth hormone (GH) have been extensively used to study the chronic effects of elevated serum levels of GH. GH is known to have many acute effects in the liver, but little is known about the chronic effects of GH overexpression on hepatic gene expression. Therefore, we used DNA microarray to compare gene expression in livers from bovine GH (bGH)-transgenic mice and littermates. Hepatic expression of peroxisome proliferator-activated receptor- (PPAR) and genes involved in fatty acid activation, peroxisomal and mitochondrial -oxidation, and production of ketone bodies was decreased. In line with this expression profile, bGH-transgenic mice had a reduced ability to form ketone bodies in both the fed and fasted states. Although the bGH mice were hyperinsulinemic, the expression of sterol regulatory element-binding protein (SREBP)-1 and most lipogenic enzymes regulated by SREBP-1 was reduced, indicating that these mice are different from other insulin-resistant models with respect to expression of SREBP-1 and its downstream genes. This study also provides several candidate genes for the well-known association between elevated GH levels and cardiovascular disease, e.g., decreased expression of scavenger receptor class B type I, hepatic lipase, and serum paraoxonase and increased expression of serum amyloid A-3 protein. We conclude that bGH-transgenic mice display marked changes in hepatic genes coding for metabolic enzymes and suggest that GH directly or indirectly regulates many of these hepatic genes via decreased expression of PPAR and SREBP-1. [PERIODICAL ABSTRACT]
ISSN:0193-1849
1522-1555